阿那白滞素对秋水仙碱抵抗且依赖糖皮质激素的复发性心包炎患者的疗效:AIRTRIP随机临床试验
AIRTRIP双盲安慰剂对照随机撤药试验纳入21例秋水仙碱抵抗且依赖糖皮质激素的复发性心包炎患者,先开放标签使用阿那白滞素2个月,应答者随机继续阿那白滞素(n=11)或换用安慰剂(n=10)6个月。安慰剂组10例中9例(90%)复发,阿那白滞素组11例中2例(18.2%)复发,发生率差为-1.95%(95%CI,-3.3%至-0.6%),无复发生存期在安慰剂组为72天(四分位距64-150天),阿那白滞素组未达到(P<.001)。
要点
- 安慰剂组复发9/10例(90%),阿那白滞素组复发2/11例(18.2%)。
- 复发发生率差为-1.95%(95%CI,-3.3%至-0.6%)。
- 阿那白滞素治疗期间20/21例(95.2%)出现一过性局部皮肤反应。
核心结论
- 在这项初步研究中,与安慰剂相比,阿那白滞素降低了秋水仙碱抵抗且依赖糖皮质激素的复发性心包炎患者在中位14个月随访内的复发风险。
- 需要更大规模的研究来重复这些发现,并评估安全性和长期疗效。
研究设计与样本
- AIRTRIP为双盲、安慰剂对照、随机撤药试验,先开放标签使用阿那白滞素,随后进行双盲撤药步骤,使用阿那白滞素或安慰剂直至复发性心包炎发生。
- 2014年6月至11月在3家意大利转诊中心连续纳入21例患者,末次随访为2015年10月。
- 纳入标准为复发性心包炎(既往复发≥3次)、C反应蛋白升高、秋水仙碱抵抗和糖皮质激素依赖。
- 阿那白滞素以2 mg/kg每日给药,最大剂量100 mg,治疗2个月后,心包炎缓解的应答者随机继续阿那白滞素(n=11)或换用安慰剂(n=10)6个月或直至心包炎复发。
主要发现
- 随机分配至阿那白滞素的11例患者(7例女性)平均年龄为46.5岁(标准差16.3岁);随机分配至安慰剂的10例患者(7例女性)平均年龄为44岁(标准差12.5岁)。
- 所有患者随访12个月,中位随访时间为14个月(范围12-17个月)。
- 安慰剂组10例中9例(90%;发生率,每年2.06%患者)发生复发性心包炎,阿那白滞素组11例中2例(18.2%;发生率,每年0.11%患者)发生复发性心包炎,发生率差为-1.95%(95%CI,-3.3%至-0.6%)。
- 随机分组后中位无复发生存期(至复发时间)在安慰剂组为72天(四分位距64-150天),在阿那白滞素组未达到(P<.001)。
- 阿那白滞素治疗期间,21例中20例(95.2%)出现一过性局部皮肤反应:1例(4.8%)带状疱疹,3例(14.3%)转氨酶升高,1例(4.8%)缺血性视神经病变;无患者永久停用活性药物;安慰剂治疗期间无不良事件发生。
临床怎么用
- 作者认为,在这项初步研究中,与安慰剂相比,阿那白滞素降低了秋水仙碱抵抗且依赖糖皮质激素的复发性心包炎患者在中位14个月随访内的复发风险。
- 作者建议需要更大规模的研究来重复这些发现,并评估安全性和长期疗效。
局限性
- 原文结论指出这是一项初步研究。
- 原文结论指出需要更大规模的研究来重复这些发现,并评估安全性和长期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Anakinra, an interleukin 1β recombinant receptor antagonist, may have potential to treat colchicine-resistant and corticosteroid-dependent recurrent pericarditis. OBJECTIVE: To determine the efficacy of anakinra for colchicine-resistant and corticosteroid-dependent recurrent pericarditis. DESIGN, SETTING, AND PARTICIPANTS: The Anakinra-Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP) double-blind, placebo-controlled, randomized withdrawal trial (open label with anakinra followed by a double-blind withdrawal step with anakinra or placebo until recurrent pericarditis occurred) conducted among 21 consecutive patients enrolled at 3 Italian referral centers between June and November 2014 (end of follow-up, October 2015). Included patients had recurrent pericarditis (with ≥3 previous recurrences), elevation of C-reactive protein, colchicine resistance, and corticosteroid dependence. INTERVENTIONS: Anakinra was administered at 2 mg/kg per day, up to 100 mg, for 2 months, then patients who responded with resolution of pericarditis were randomized to continue anakinra (n = 11) or switch to placebo (n = 10) for 6 months or until a pericarditis recurrence. MAIN OUTCOMES AND MEASURES: The primary outcomes were recurrent pericarditis and time to recurrence after randomization. RESULTS: Eleven patients (7 female) randomized to anakinra had a mean age of 46.5 (SD, 16.3) years; 10 patients (7 female) randomized to placebo had a mean age of 44 (SD, 12.5) years. All patients were followed up for 12 months. Median follow-up was 14 (range, 12-17) months. Recurrent pericarditis occurred in 9 of 10 patients (90%; incidence rate, 2.06% of patients per year) assigned to placebo and 2 of 11 patients (18.2%; incidence rate, 0.11% of patients per year) assigned to anakinra, for an incidence rate difference of -1.95% (95% CI, -3.3% to -0.6%). Median flare-free survival (time to flare) was 72 (interquartile range, 64-150) days after randomization in the placebo group and was not reached in the anakinra group (P <.001). During anakinra treatment, 20 of 21 patients (95.2%) experienced transient local skin reactions: 1 (4.8%) herpes zoster, 3 (14.3%) transaminase elevation, and 1 (4.8%) ischemic optic neuropathy. No patient permanently discontinued the active drug. No adverse events occurred during placebo treatment. CONCLUSION AND RELEVANCE: In this preliminary study of patients with recurrent pericarditis with colchicine resistance and corticosteroid dependence, the use of anakinra compared with placebo reduced the risk of recurrence over a median of 14 months. Larger studies are needed to replicate these findings as well as to assess safety and longer-term efficacy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02219828.
引用
- Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016. PMID: 27825009. doi:10.1001/jama.2016.15826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。